We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

FDG-PET Imaging in Young Cystic Fibrosis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00846053
Recruitment Status : Unknown
Verified March 2011 by Washington University School of Medicine.
Recruitment status was:  Recruiting
First Posted : February 18, 2009
Last Update Posted : March 4, 2011
Cystic Fibrosis Foundation Therapeutics
Information provided by:
Washington University School of Medicine

Brief Summary:
The purpose of this research is to determine how a person's lungs will uptake [18F]fluorodeoxyglucose (FDG), as measured with positron emission tomography (PET) scanning in young cystic fibrosis patients.

Condition or disease Intervention/treatment
Cystic Fibrosis Procedure: [18F]FDG PET/CT

Detailed Description:
Our recent study in CF adults, supplemented by recent pre-clinical and clinical studies by our group suggests that FDG-PET imaging may be a valuable quantitative biomarker of lung inflammation. The proposed study would validate our earlier findings, but in a younger patient population. The implications of such a test could be highly significant for both the testing of promising new anti-inflammatory agents and for patient management decisions. To capitalize on this exciting opportunity, the critical next step is to show that we can identify a cohort of young CF patients with both stable lung function and normal (or near normal) FDG-PET imaging studies. Similar patients, then, would become the subjects for a future prospective cohort study to determine if FDG-PET imaging can in fact serve as a predictor of future changes in lung function.

Study Type : Observational
Estimated Enrollment : 28 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: FDG-PET Imaging in Young Cystic Fibrosis Patients
Study Start Date : February 2009
Estimated Primary Completion Date : February 2012
Estimated Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis
U.S. FDA Resources

Group/Cohort Intervention/treatment
  • Group S (n = 14) will consist of CF patients, aged 12-21 years old, with stable lung function during the past 4 years, defined as less than 2% decline per year [21,26].
  • Group R (n = 14) will contain CF patients, aged 12-21 years old, with rapidly deteriorating lung function during the past 4 years with greater than 4% per year decline
Procedure: [18F]FDG PET/CT
FDA-approved Investigational New Drug (IND) to use [18F]FDG in CF patients under the age of 18 years (PI: Robert Mach, MD, IND # 76079). Imaging data will be acquired with a Siemens Biograph 40PET/CT Tomograph. Research participants will be positioned supine in the scanner and a scout CT topograph obtained.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Our Pediatric Cystic Fibrosis Clinic currently has 124 patients between the ages of 12 and 21 years. We will need to recruit patients from this clinic population, plus new patients that enter the clinic over the 2 to 3 year period.

Inclusion Criteria:

  • Confirmed diagnosis of cystic fibrosis
  • Age 12 to 21 years old, of either gender, any race or ethnicity
  • Stable recent pulmonary status (defined as no new pulmonary symptoms, new antibiotic use, or hospitalization for pulmonary symptoms for at least 1 month).
  • We will permit patients treated with the macrolide antibiotic, azithromycin, to participate in this study. Azithromycin has recently become a virtual standard of care in CF [36], based on small but reproducible improvements in pulmonary function over 4 months of treatment with this drug. The mechanism of benefit is uncertain, but an anti-inflammatory effect has been suggested [36]. The high prevalence of use means that a study without azithromycin would likely require a wash-out period, without data about the appropriate duration for such a wash-out, or whether inflammatory markers would reverse during that time.

Exclusion Criteria:

  • Failure to obtain informed consent
  • Positive pregnancy test or lactation
  • Currently enrolled in another study involving radioisotopes or an investigational drug
  • Recent (within 30 days of screening) hospitalization for any reason
  • New antibiotic use (within 30 days of screening).
  • Patient incapable of lying still and supine within the PET/CT scanner for 90 minutes.
  • Patient incapable of completing other testing procedures (e.g., PFT, induced sputum)
  • Patient with serum glucose greater than 150 mg/dl at time of PET imaging study
  • Patient incapable of fasting for 4 to 6 hrs prior to PET imaging study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00846053

Contact: Thomas W Ferkol, MD 314-454-2694 ferkol_t@wustl.edu
Contact: Mary G Boyle, RN 314-454-4609 boyle@kids.wustl.edu

United States, Missouri
Washington University School of Medicine Recruiting
St. Louis, Missouri, United States, 63110
Contact: Thomas W Ferkol, MD    314-454-2694    ferkol_t@wustl.edu   
Contact: Mary G Boyle, RN, MSN    314-454-4609    boyle@kids.wustl.edu   
Principal Investigator: Thomas W Ferkol, MD         
Sponsors and Collaborators
Washington University School of Medicine
Cystic Fibrosis Foundation Therapeutics
Principal Investigator: Thomas Ferkol, MD Washington University School of Medicine

Responsible Party: Tholmas W. Ferkol, MD, Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT00846053     History of Changes
Other Study ID Numbers: 08-1219
First Posted: February 18, 2009    Key Record Dates
Last Update Posted: March 4, 2011
Last Verified: March 2011

Additional relevant MeSH terms:
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases